Otsuka's monoclonal antibody Voyxact has received FDA approval for the treatment of primary IgA nephropathy (IgAN) in people who are at risk of the illness progressing. Following Phase 3 data showing notable and long-lasting decreases in proteinuria, the permission was granted. Voyxact is given once every four weeks, and options for at-home administration are anticipated to increase therapy accessibility. Data on long-term renal outcomes are still being gathered.
Source Reference:
FDA Approval Announcement:
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-voyxact-iga-nephropathy
Disclaimer: The information presented in this article is for informational and educational purposes only. While every effort has been made to ensure data accuracy and reliability, readers are advised to independently verify all figures, regulations, and market insights before making any business or investment decisions.